Cargando…

Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study

AIM: A metabolomics approach has recently been used to identify metabolites associated with response to antipsychotic treatment. This study was designed to identify the predictive biomarkers of response to olanzapine monotherapy using a metabolomics‐based strategy. METHODS: Twenty‐five first‐episode...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiaoni, Xu, Jing, Xiu, Meihong, Li, Xirong, Liu, Haixia, Wu, Fengchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437236/
https://www.ncbi.nlm.nih.gov/pubmed/35769008
http://dx.doi.org/10.1111/cns.13895
_version_ 1784781540756029440
author Guan, Xiaoni
Xu, Jing
Xiu, Meihong
Li, Xirong
Liu, Haixia
Wu, Fengchun
author_facet Guan, Xiaoni
Xu, Jing
Xiu, Meihong
Li, Xirong
Liu, Haixia
Wu, Fengchun
author_sort Guan, Xiaoni
collection PubMed
description AIM: A metabolomics approach has recently been used to identify metabolites associated with response to antipsychotic treatment. This study was designed to identify the predictive biomarkers of response to olanzapine monotherapy using a metabolomics‐based strategy. METHODS: Twenty‐five first‐episode and drug‐naïve female patients with schizophrenia were recruited and treated with olanzapine for 4 weeks. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and 4‐week follow‐up. RESULTS: Positive subscore, general psychopathology subscore, and PANSS total score were significantly decreased after treatment. An ultra‐performance liquid chromatography‐mass spectrometry (UPLC‐MS)‐based metabolomics approach identified 72 differential metabolites after treatment. In addition, the baseline levels of methyl n‐formylanthranilate (MNFT) were correlated with the rate of reduction in the positive subscore or PANSS total score. However, increase in MNFT after treatment was not associated with the rate of reduction in the PANSS total score or its subscores. Subsequent regression analysis revealed that the baseline MNFT levels predicted the treatment outcomes after olanzapine monotherapy for 4 weeks in patients with schizophrenia. CONCLUSIONS: Our study results suggest that the baseline MNFT levels in the kynurenine pathway of tryptophan metabolism may be predictive of the treatment response to olanzapine in schizophrenia.
format Online
Article
Text
id pubmed-9437236
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94372362022-09-09 Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study Guan, Xiaoni Xu, Jing Xiu, Meihong Li, Xirong Liu, Haixia Wu, Fengchun CNS Neurosci Ther Original Articles AIM: A metabolomics approach has recently been used to identify metabolites associated with response to antipsychotic treatment. This study was designed to identify the predictive biomarkers of response to olanzapine monotherapy using a metabolomics‐based strategy. METHODS: Twenty‐five first‐episode and drug‐naïve female patients with schizophrenia were recruited and treated with olanzapine for 4 weeks. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and 4‐week follow‐up. RESULTS: Positive subscore, general psychopathology subscore, and PANSS total score were significantly decreased after treatment. An ultra‐performance liquid chromatography‐mass spectrometry (UPLC‐MS)‐based metabolomics approach identified 72 differential metabolites after treatment. In addition, the baseline levels of methyl n‐formylanthranilate (MNFT) were correlated with the rate of reduction in the positive subscore or PANSS total score. However, increase in MNFT after treatment was not associated with the rate of reduction in the PANSS total score or its subscores. Subsequent regression analysis revealed that the baseline MNFT levels predicted the treatment outcomes after olanzapine monotherapy for 4 weeks in patients with schizophrenia. CONCLUSIONS: Our study results suggest that the baseline MNFT levels in the kynurenine pathway of tryptophan metabolism may be predictive of the treatment response to olanzapine in schizophrenia. John Wiley and Sons Inc. 2022-06-29 /pmc/articles/PMC9437236/ /pubmed/35769008 http://dx.doi.org/10.1111/cns.13895 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Guan, Xiaoni
Xu, Jing
Xiu, Meihong
Li, Xirong
Liu, Haixia
Wu, Fengchun
Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title_full Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title_fullStr Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title_full_unstemmed Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title_short Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
title_sort kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: a longitudinal study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437236/
https://www.ncbi.nlm.nih.gov/pubmed/35769008
http://dx.doi.org/10.1111/cns.13895
work_keys_str_mv AT guanxiaoni kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy
AT xujing kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy
AT xiumeihong kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy
AT lixirong kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy
AT liuhaixia kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy
AT wufengchun kynureninepathwaymetabolitesandtherapeuticresponsetoolanzapineinfemalepatientswithschizophreniaalongitudinalstudy